Dr. Michel Sabé - Psychedelics & Schizophrenia: Rethinking Care for Negative and Depressive symptoms

Value of the Information & Strength of the Argument

The talk provides valuable insights into a highly debated topic, offering a balanced view that acknowledges both potential benefits and risks. The speaker supports his arguments with references to specific studies and clinical experiences, which adds credibility. However, the argumentation is largely based on preliminary data and anecdotal evidence, and the speaker does not critically appraise the limitations of the cited studies. The discussion of phenomenological subtypes of psychosis is informative and helps contextualize the risks. Overall, the value lies in its clinical perspective and the call for further research, but the evidence base is not yet robust.

Scientific Rigor, Source Quality, Title Accuracy

The speaker demonstrates scientific rigor by referencing several recent studies and meta-analyses, and he transparently mentions his own research group’s work. However, he does not provide full citations for all studies mentioned, and some claims are based on personal communications. The title accurately reflects the content, which is focused on rethinking care for negative and depressive symptoms in SSD using psychedelics. The talk is well-structured and clinically grounded, but the lack of detailed references for some statements slightly reduces the overall rigor.

The title accurately reflects the content, which focuses on the potential use of psychedelics for negative and depressive symptoms in schizophrenia spectrum disorders.

7/10

The talk is based on clinical experience and recent studies, but it is an expert opinion rather than a systematic review. The speaker cites several specific studies and personal communications, but some claims lack detailed references. The content is scientifically plausible and aligns with current research trends, but the evidence base is still preliminary.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to psychosis and its symptoms
• 05:00Discussion of negative and depressive symptoms prevalence
• 10:00Phenomenology of different psychosis subtypes
• 15:00Risk of exacerbation and transition to psychosis
• 20:00Arguments for and against psychedelic use in SSD
• 25:00Mechanisms of action: default mode network and neuroplasticity
• 30:00Differentiating negative and depressive symptoms
• 35:00Evidence from meta-analyses on antidepressants in SSD
• 40:00Emerging trials: psilocybin in Parkinson's and bipolar type 2
• 45:00Case report of psilocybin in schizoaffective disorder

• Study on stimulants in schizophrenia (Rohde et al., 2017) — Mentioned as evidence for benefits of psychostimulants in SSD
• Study on stimulants in SSD (Lukes et al., 2025) — Large cohort study on lisdexamfetamine, atomoxetine, and methylphenidate
• Chinese study on antipsychotics and stimulants (Zhang et al., 2021) — Proportion of patients receiving stimulants and outcomes
• Paper by Joseph Latoya on psychedelic use in SSD — Cited as evidence that some individuals with SSD use psychedelics responsibly
• Meta-analysis on antidepressants in schizophrenia (Lush group) — Effects on negative and depressive symptoms
• Open-label pilot trial of psilocybin in Parkinson's disease (2025) — Significant improvement in depression and anxiety without serious adverse events
• Non-randomized trial of psilocybin in bipolar type 2 depression — Reduction in depression scores with no manic or suicidal events
• MDMA study for schizophrenia at University of California — Open-label ascending dose trial, no severe adverse events so far

• Psychedelics and schizophrenia: a systematic review — Supports the potential for psychedelics in SSD with careful selection
• Psilocybin for treatment-resistant depression — Shows efficacy in depression, which may extend to depressive symptoms in SSD

• Risk of psychosis with psychedelics — Some studies emphasize the risk of triggering psychosis in vulnerable individuals, which the speaker acknowledges but downplays.